SRR662978
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.474
- OXIDATIVE_PHOSPHORYLATION+0.420
- MYOGENESIS+0.407
- HYPOXIA+0.347
- ADIPOGENESIS+0.341
- FATTY_ACID_METABOLISM+0.320
- ESTROGEN_RESPONSE_LATE+0.317
- XENOBIOTIC_METABOLISM+0.296
- HEDGEHOG_SIGNALING+0.280
- INFLAMMATORY_RESPONSE+0.272
Top 10 suppressed
- G2M_CHECKPOINT-0.443
- E2F_TARGETS-0.390
- MYC_TARGETS_V2-0.390
- MITOTIC_SPINDLE-0.316
- MYC_TARGETS_V1-0.231
- PROTEIN_SECRETION-0.210
- WNT_BETA_CATENIN_SIGNALING-0.174
- DNA_REPAIR-0.149
- UNFOLDED_PROTEIN_RESPONSE-0.121
- INTERFERON_ALPHA_RESPONSE-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1487685 | GTEX | — | 0.869 |
| 2 | SJEPD021_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.868 |
| 3 | SRR1399051 | GTEX | — | 0.862 |
| 4 | SRR1320560 | GTEX | — | 0.858 |
| 5 | TCGA-BH-A0HF-01A-11R-A056-07 | — | A | 0.858 |
| 6 | MDT-AP-0385 | Med | Medulloblastoma | 0.852 |
| 7 | TCGA-21-5784-01A-01R-1635-07 | — | cohortSQ1 | 0.848 |
| 8 | SRR1328487 | GTEX | — | 0.846 |
| 9 | BS_NB5XWMJT | low-grade glioma | — | 0.844 |
| 10 | BS_680K119G | Ganglioglioma | — | 0.836 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.474 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.420 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.407 | Inavolisib | — uncovered |
| HYPOXIA | 0.347 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.341 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.320 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.317 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.296 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.272 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.271 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.268 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.256 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.254 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.243 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.216 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.212 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.201 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.191 | Inavolisib | — uncovered |